Literature DB >> 33750332

Clinical characteristics and outcomes of patients admitted to hospitals for posterior reversible encephalopathy syndrome: a retrospective cohort study.

Abbas Alshami1, Asseel Al-Bayati1, Steven Douedi2, Mohammad A Hossain1, Swapnil Patel1, Arif Asif1.   

Abstract

BACKGROUND: Posterior reversible encephalopathy syndrome (PRES) is usually a benign, yet underdiagnosed clinical condition associated with subacute to acute neurological manifestations primarily affecting white matter. PRES is reversible when recognized promptly and treated early by removal of the insulting factor; however, can lead to irreversible and life-threatening complications such as cerebral hemorrhage, cerebellar herniation, and refractory status epilepticus.
METHODS: We utilized the National Inpatient Sample database provided by the Healthcare Cost and Utilization Project (HCUP-NIS) 2017 to investigate the demographic variables (age, sex, and race) for patients with PRES, concomitant comorbidities and conditions, inpatient complications, inpatient mortality, length of stay (LOS), and disposition.
RESULTS: A total of 635 admissions for patients aged 18 years or older with PRES were identified. The mean age was 57.2 ± 0.6 years old with most encounters for female patients (71.7%, n = 455) and white as the most prevalent race. Half the patients in our study presented with seizures (50.1%, n = 318), sixty-three patients (9.9%) presented with vision loss, and sixty-four patients (10.1%) had speech difficulty. In addition, 45.5% of patients had hypertensive crisis (n = 289). 2.2% of hospitalizations had death as the outcome (n = 14). The mean LOS was 8.2 (±0.3) days, and the mean total charges were $92,503 (±$5758). Inpatient mortality differed between males and females (1.7% vs. 2.4%) and by race (3.6% in black vs. 1.8% in white) but was ultimately determined to be not statistically significant. Most patients who present with vision disturbance have a high risk of intracranial hemorrhage. Furthermore, end-stage renal disease, atrial fibrillation, and malignancy seemed to be linked with a very high risk of mortality.
CONCLUSION: PRES, formerly known as reversible posterior leukoencephalopathy, is a neurological disorder with variable presenting symptoms. Although it is generally a reversible condition, some patients suffer significant morbidity and even mortality. To the best of our knowledge, this is the largest retrospective cohort of PRES admissions that raises clinician awareness of clinical characteristics and outcomes of this syndrome.

Entities:  

Keywords:  Cerebral hemorrhage; Neurologic complications; Posterior reversible encephalopathy syndrome; Seizures

Mesh:

Year:  2021        PMID: 33750332      PMCID: PMC7941613          DOI: 10.1186/s12883-021-02143-6

Source DB:  PubMed          Journal:  BMC Neurol        ISSN: 1471-2377            Impact factor:   2.474


  32 in total

1.  Posterior reversible encephalopathy syndrome in infection, sepsis, and shock.

Authors:  W S Bartynski; J F Boardman; Z R Zeigler; R K Shadduck; J Lister
Journal:  AJNR Am J Neuroradiol       Date:  2006 Nov-Dec       Impact factor: 3.825

2.  Spectrum and potential pathogenesis of reversible posterior leukoencephalopathy syndrome.

Authors:  Yuebing Li; Devang Gor; Debra Walicki; Donna Jenny; David Jones; Peter Barbour; John Castaldo
Journal:  J Stroke Cerebrovasc Dis       Date:  2011-06-23       Impact factor: 2.136

3.  Posterior reversible encephalopathy syndrome: the endothelial hypotheses.

Authors:  A Marra; M Vargas; P Striano; L Del Guercio; P Buonanno; G Servillo
Journal:  Med Hypotheses       Date:  2014-03-01       Impact factor: 1.538

Review 4.  Controversy of posterior reversible encephalopathy syndrome: what have we learnt in the last 20 years?

Authors:  Bo Gao; Cui Lyu; Alexander Lerner; Alexander M McKinney
Journal:  J Neurol Neurosurg Psychiatry       Date:  2017-08-09       Impact factor: 10.154

5.  Posterior reversible encephalopathy syndrome (PRES) and infection: a systematic review of the literature.

Authors:  Sergio Racchiusa; Enricomaria Mormina; Antonietta Ax; Olimpia Musumeci; Marcello Longo; Francesca Granata
Journal:  Neurol Sci       Date:  2019-01-02       Impact factor: 3.307

6.  Reversible posterior leukoencephalopathy, cerebral vasoconstriction, and strokes after intravenous immune globulin therapy in guillain-barre syndrome.

Authors:  Christine E Doss-Esper; Aneesh B Singhal; Marsha S A Smith; Galen V Henderson
Journal:  J Neuroimaging       Date:  2005-04       Impact factor: 2.486

Review 7.  [A reversible posterior leukoencephalopathy syndrome].

Authors:  F López-García; F Amorós-Martínez; A P Sempere
Journal:  Rev Neurol       Date:  2004 Feb 1-15       Impact factor: 0.870

8.  Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome.

Authors:  W S Bartynski; J F Boardman
Journal:  AJNR Am J Neuroradiol       Date:  2007-08       Impact factor: 3.825

9.  Principled missing data methods for researchers.

Authors:  Yiran Dong; Chao-Ying Joanne Peng
Journal:  Springerplus       Date:  2013-05-14

10.  Posterior Reversible Encephalopathy Syndrome in a Bone Marrow Transplant Patient: A Complication of Immunosuppressive Drugs?

Authors:  Mohammad A Hossain; Waqas Jehangir; Qiang Nai; Naureen Jessani; Rafay Khan; Abdalla Yousif; Shuvendu Sen
Journal:  World J Oncol       Date:  2015-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.